TY - JOUR
T1 - Role of the parental NF1 carrier in effects of pharmacological inhibition of anaplastic lymphoma kinase in Neurofibromatosis 1 mutant mice
AU - Krenik, Destine
AU - Weiss, Joseph B.
AU - Raber, Jacob
N1 - Funding Information:
The authors would like to thank Sarah Holden, Ruby Perez, Sydney Boutros, Eileen Ruth Samson Torres, and Payel Kundu for their help with the preparation and daily feeding of the mice for this study. This work was supported by Department of Defense Neurofibromatosis Research Program (NFRP) Award W81XWH-17-1-0193. The graphical abstract was generated using Biorender software.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/10/15
Y1 - 2021/10/15
N2 - Neurofibromatosis type 1 (NF1), a genetically determined neurodevelopmental disorder and tumor syndrome, is associated with cognitive impairments, including in executive function and sleep-related problems. Consistent with the human data, NF1 heterozygous (Het) mice show impaired spatial learning and memory in the water maze and extinction of contextual fear memory. It is not clear whether neurological phenotypes might depend on the parental carrier. In this study, we compared the behavioral and cognitive performance of NF1 Het and wild-type litter mates with either the father (PC) or the mother (MC) as the NF1 carrier on a F1 C57BL/66/129SvJ background. The behavioral and cognitive phenotypes and responsiveness to Alk inhibition in heterozygous NF1 offspring depended on whether the parental carrier was maternal or paternal. Alk inhibition (20 mg/kg) increased activity levels during the dark period in NF1 Het PC, but not MC, mice. In the water maze, NF1 Het PC, but not MC, mice showed reduced cognitive flexibility and impaired ability to locate the third hidden platform location, which was improved by Alk inhibition (3.6 mg/kg). Consistent with reduced cognitive flexibility, WT, but not NF1, mice showed better performance in the third than second water maze probe trial. Finally, Alk inhibition (10 mg/kg) increased baseline activity of NF1 MC, but not PC, mice during the fear conditioning test. Thus, the effective dose depends on the behavioral test and genotype but indicates that in NF1 patients cognitive flexibility might be particularly sensitive to Alk inhibition.
AB - Neurofibromatosis type 1 (NF1), a genetically determined neurodevelopmental disorder and tumor syndrome, is associated with cognitive impairments, including in executive function and sleep-related problems. Consistent with the human data, NF1 heterozygous (Het) mice show impaired spatial learning and memory in the water maze and extinction of contextual fear memory. It is not clear whether neurological phenotypes might depend on the parental carrier. In this study, we compared the behavioral and cognitive performance of NF1 Het and wild-type litter mates with either the father (PC) or the mother (MC) as the NF1 carrier on a F1 C57BL/66/129SvJ background. The behavioral and cognitive phenotypes and responsiveness to Alk inhibition in heterozygous NF1 offspring depended on whether the parental carrier was maternal or paternal. Alk inhibition (20 mg/kg) increased activity levels during the dark period in NF1 Het PC, but not MC, mice. In the water maze, NF1 Het PC, but not MC, mice showed reduced cognitive flexibility and impaired ability to locate the third hidden platform location, which was improved by Alk inhibition (3.6 mg/kg). Consistent with reduced cognitive flexibility, WT, but not NF1, mice showed better performance in the third than second water maze probe trial. Finally, Alk inhibition (10 mg/kg) increased baseline activity of NF1 MC, but not PC, mice during the fear conditioning test. Thus, the effective dose depends on the behavioral test and genotype but indicates that in NF1 patients cognitive flexibility might be particularly sensitive to Alk inhibition.
KW - Alk inhibition
KW - Fear conditioning
KW - Mice
KW - NF1
KW - Parental carrier
KW - Water maze
UR - http://www.scopus.com/inward/record.url?scp=85112486007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112486007&partnerID=8YFLogxK
U2 - 10.1016/j.brainres.2021.147594
DO - 10.1016/j.brainres.2021.147594
M3 - Article
C2 - 34339711
AN - SCOPUS:85112486007
SN - 0006-8993
VL - 1769
JO - Brain research
JF - Brain research
M1 - 147594
ER -